These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 21295122)

  • 1. Sulfation of the 3,4-methylenedioxymethamphetamine (MDMA) metabolites 3,4-dihydroxymethamphetamine (DHMA) and 4-hydroxy-3-methoxymethamphetamine (HMMA) and their capability to inhibit human sulfotransferases.
    Schwaninger AE; Meyer MR; Zapp J; Maurer HH
    Toxicol Lett; 2011 Apr; 202(2):120-8. PubMed ID: 21295122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation on the enantioselectivity of the sulfation of the methylenedioxymethamphetamine metabolites 3,4-dihydroxymethamphetamine and 4-hydroxy-3-methoxymethamphetamine using the substrate-depletion approach.
    Schwaninger AE; Meyer MR; Maurer HH
    Drug Metab Dispos; 2011 Nov; 39(11):1998-2002. PubMed ID: 21795466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct determination of glucuronide and sulfate of 4-hydroxy-3-methoxymethamphetamine, the main metabolite of MDMA, in human urine.
    Shima N; Kamata H; Katagi M; Tsuchihashi H; Sakuma T; Nemoto N
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Sep; 857(1):123-9. PubMed ID: 17643356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of human UDP-glucuronyltransferases on the formation of the methylenedioxymethamphetamine (ecstasy) phase II metabolites R- and S-3-methoxymethamphetamine 4-O-glucuronides.
    Schwaninger AE; Meyer MR; Zapp J; Maurer HH
    Drug Metab Dispos; 2009 Nov; 37(11):2212-20. PubMed ID: 19666989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary excretion kinetics of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its phase I and phase II metabolites in humans following controlled MDMA administration.
    Schwaninger AE; Meyer MR; Barnes AJ; Kolbrich-Spargo EA; Gorelick DA; Goodwin RS; Huestis MA; Maurer HH
    Clin Chem; 2011 Dec; 57(12):1748-56. PubMed ID: 21980168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary excretion of the main metabolites of 3,4-methylenedioxymethamphetamine (MDMA), including the sulfate and glucuronide of 4-hydroxy-3-methoxymethamphetamine (HMMA), in humans and rats.
    Shima N; Katagi M; Kamata H; Zaitsu K; Kamata T; Nishikawa M; Miki A; Tsuchihashi H; Sakuma T; Nemoto N
    Xenobiotica; 2008 Mar; 38(3):314-24. PubMed ID: 18274959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of an LC-MS/MS method after chiral derivatization for the simultaneous stereoselective determination of methylenedioxy-methamphetamine (MDMA) and its phase I and II metabolites in human blood plasma.
    Steuer AE; Schmidhauser C; Liechti ME; Kraemer T
    Drug Test Anal; 2015 Jul; 7(7):592-602. PubMed ID: 25371386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") and its major metabolites in squirrel monkeys at plasma concentrations of MDMA that develop after typical psychoactive doses.
    Mueller M; Peters FT; Maurer HH; McCann UD; Ricaurte GA
    J Pharmacol Exp Ther; 2008 Oct; 327(1):38-44. PubMed ID: 18591215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gas chromatography-ion trap mass spectrometry method for the simultaneous measurement of MDMA (ecstasy) and its metabolites, MDA, HMA, and HMMA in plasma and urine.
    da Silva DG; de Pinho PG; Pontes H; Ferreira L; Branco P; Remião F; Carvalho F; Bastos ML; Carmo H
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Mar; 878(9-10):815-22. PubMed ID: 20167546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus.
    Forsling ML; Fallon JK; Shah D; Tilbrook GS; Cowan DA; Kicman AT; Hutt AJ
    Br J Pharmacol; 2002 Feb; 135(3):649-56. PubMed ID: 11834612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enantioselective determination of 3,4-methylene-dioxymethamphetamine and two of its metabolites in human urine by cyclodextrin-modified capillary zone electrophoresis.
    Lanz M; Brenneisen R; Thormann W
    Electrophoresis; 1997 Jun; 18(6):1035-43. PubMed ID: 9221895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chiral Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine and its Phase I and II Metabolites following Controlled Administration to Humans.
    Steuer AE; Schmidhauser C; Schmid Y; Rickli A; Liechti ME; Kraemer T
    Drug Metab Dispos; 2015 Dec; 43(12):1864-71. PubMed ID: 26395866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of 3,4-methylenedioxymethamphetamine (MDMA) and its main metabolites on cardiovascular function in conscious rats.
    Schindler CW; Thorndike EB; Blough BE; Tella SR; Goldberg SR; Baumann MH
    Br J Pharmacol; 2014 Jan; 171(1):83-91. PubMed ID: 24328722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans.
    Abraham TT; Barnes AJ; Lowe RH; Kolbrich Spargo EA; Milman G; Pirnay SO; Gorelick DA; Goodwin RS; Huestis MA
    J Anal Toxicol; 2009 Oct; 33(8):439-46. PubMed ID: 19874650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Case of 3,4-Dimethoxyamphetamine (3,4-DMA) and 3,4-Methylenedioxymethamphetamine (MDMA) Toxicity with Possible Metabolic Interaction.
    Darracq MA; Thornton SL; Minns AB; Gerona RR
    J Psychoactive Drugs; 2016; 48(5):351-354. PubMed ID: 27636207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxylated serotonin and dopamine as substrates and inhibitors for human cytosolic SULT1A3.
    Yasuda S; Liu MY; Suiko M; Sakakibara Y; Liu MC
    J Neurochem; 2007 Dec; 103(6):2679-89. PubMed ID: 17908235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine).
    Pizarro N; Farré M; Pujadas M; Peiró AM; Roset PN; Joglar J; de la Torre R
    Drug Metab Dispos; 2004 Sep; 32(9):1001-7. PubMed ID: 15319342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Further studies on the role of metabolites in (+/-)-3,4-methylenedioxymethamphetamine-induced serotonergic neurotoxicity.
    Mueller M; Yuan J; Felim A; Neudörffer A; Peters FT; Maurer HH; McCann UD; Largeron M; Ricaurte GA
    Drug Metab Dispos; 2009 Oct; 37(10):2079-86. PubMed ID: 19628751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-Hydroxy-3-methoxymethamphetamine glucuronide as a phase II metabolite of 3,4-methylenedioxymethamphetamine: enzyme-assisted synthesis and involvement of human hepatic uridine 5'-diphosphate-glucuronosyltransferase 2B15 in the glucuronidation.
    Shoda T; Fukuhara K; Goda Y; Okuda H
    Chem Pharm Bull (Tokyo); 2009 May; 57(5):472-5. PubMed ID: 19420777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic interactions between ethanol and MDMA in primary cultured rat hepatocytes.
    Pontes H; de Pinho PG; Fernandes E; Branco PS; Ferreira LM; Carmo H; Remião F; Carvalho F; Bastos ML
    Toxicology; 2010 Apr; 270(2-3):150-7. PubMed ID: 20170704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.